GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SLS BIO Co Ltd (XKRX:246250) » Definitions » Net Income From Continuing Operations

SLS BIO Co (XKRX:246250) Net Income From Continuing Operations : ₩1,502 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SLS BIO Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. SLS BIO Co's net income from continuing operations for the three months ended in Mar. 2024 was ₩134 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₩1,502 Mil.

SLS BIO Co Net Income From Continuing Operations Historical Data

The historical data trend for SLS BIO Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SLS BIO Co Net Income From Continuing Operations Chart

SLS BIO Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only 626.93 -677.92 57.89 2,826.04 1,434.05

SLS BIO Co Quarterly Data
Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial 65.43 924.69 35.69 408.23 133.64

SLS BIO Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,502 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SLS BIO Co (XKRX:246250) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SLS BIO Co Ltd (XKRX:246250) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:303360 XKRX:149300 XKRX:109820 XKRX:086460 XKRX:236340 XKRX:229000 XKRX:347740 XKRX:031860 XKRX:221800 XKRX:245620 TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
N/A
Address
Gwanggyo Central Biz Tower, 7th floor, Changryong-dong 260, Gyeonggi-do, Suwon-si, KOR, 16229
Website
http://www.slabs.co.kr
SLS BIO Co Ltd is engaged in providing drug development supporting services and pharmaceutical product QC through general tests and assays and instrumental analysis.

SLS BIO Co (XKRX:246250) Headlines

No Headlines